SPECIAL ISSUE: PSYCHIATRY & NEUROLOGY

Journal of THE SOCIETY OF PHYSICIANS OF HONG KONG

ISSN 2072-4209



- **Major Depressive Disorder – Treatment Options Other Than SSRI**
  Dr Lam Tat Chung, Paul (林達聰醫生)
- **Long-term Treatment of Relapsing-Remitting Multiple Sclerosis**
  Dr Chan Koon Ho (陳灌豪醫生)
- **The Patient With Daily Headache**
  Dr Hui Che Fai, Andrew (許志輝醫生)

NEW

Valdoxan®

Agomelatine

The first melatonergic antidepressant

NEW AND DIFFERENT approach to depression treatment

✓ Unique and synergistic mode of action: MT_1 / MT_2 agonist and 5-HT_{2C} antagonist

✓ Resynchronization of circadian rhythms

Faster and superior, higher and more sustained efficacy

One tablet daily at bedtime

Presentation and Composition: Each film-coated tablet contains 25 mg of agomelatine. **Indication:** Treatment of major depressive episodes in adults. **Properties:** Antidepressant. Melatonergic agonist (MT_1 and MT_2 receptors) and 5-HT_{2C} antagonist. No influence on extracellular levels of serotonin. Proven antidepressant efficacy including in severe depression. Sustained antidepressant efficacy preventing relapse. Improvement of onset and quality of sleep, without daytime drowsiness from the first week of treatment. No discontinuation symptoms, or effects on sexual function, body weight, heart rate, or blood pressure. **Contraindications:** Hypersensitivity to the active substance or any excipient, hepatic impairment, concomitant use with potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin). **Dosage:** The recommended dose is 25 mg once daily taken orally at bedtime. After 2 weeks, the dose may be increased to two 25 mg tablets. **Interactions:** Combination of Valdoxan and alcohol is not advisable. **Side effects:** Common: headache, dizziness, somnolence, insomnia, migraine, nausea, diarrhea, constipation, upper abdominal pain, hyperhidrosis, back pain, fatigue, anxiety, increases serum transaminases. **Precautions:** Not recommended in patients under 18 years old, pregnant women and during breastfeeding. Not for use in elderly patients with dementia. Use with caution in patients with a history of mania or hypomania and discontinue therapy if manic symptoms appear. Possible effects on the ability to drive a car or operate machinery. Perform liver function tests when initiating treatment, periodically after around 6, 12 and 24 weeks, and thereafter when clinically indicated. Perform liver function tests in patients with symptoms suggesting hepatic dysfunction. Do not use in patients with galactose intolerance or glucose-galactose malabsorption. As prescribing information may vary from country to country, please refer to the complete data sheet supplied in your country. **LES LABORATOIRES SERVIER France.** Correspondent: **SERVIER INTERNATIONAL**: 35 rue de Verdun, 92284 Suresnes Cedex, France. www.servier.com www.valdoxan.com

Valdoxan is approved by EMEA in February 2006. Product registration of Valdoxan in Hong Kong is in process.

For further information, please contact:
Servier Hong Kong Ltd., Room 4201-03, 42/F, 248 Queen's Road East, Wan Chai, Hong Kong.
Tel: 2511 1822

servier
www.servier.com

香港內科學會
THE SOCIETY OF PHYSICIANS OF HONG KONG

www.soPHYSICIANSHK.org

Journal of THE SOCIETY OF PHYSICIANS OF HONG KONG

AUGUST 2010 • Vol. 2 • No. 5
Special Issue: Psychiatry & Neurology

CMPMedica
United Business Media

Editorial Office:
CMPMedica Pacific Ltd
9th Floor, CNT Tower, 338 Hennessy Road, Wan Chai, Hong Kong
T +852 2559 5888 F +852 2559 6910

Advertising Enquiries:
Ms Chloe Wong
T +852 2155 8557
e-mail: chloe.wong@asia.cmpmedica.com

Editorial

In primary care settings, approximately 30% to 50% of patients have prominent psychiatric symptoms or identifiable mental disorders, which are of significant adverse consequences if left untreated.[1] Even in surgical specialties, many presurgical and postsurgical developments are associated with significant mental health issues. Recent trends in medicine promote the further integration of psychiatry into the mainstream of medical practice, and emphasize the importance of attending to patients with psychiatric symptoms regardless of the clinician's medical specialty.[2] We hope this issue of the Journal will remind our readers of this important aspect of patient care.

References:

1. Weissman MM, Neria Y, Gameroff JJ, et al. Positive screens for psychiatric disorders in primary care: A long-term follow-up of patients who were not in treatment. Psychiatr Serv 2010;61:151-159.
2. David Kupfer, Darrel Regier. Why all of medicine should care about DSM-5. JAMA 2010;303:1974-1975.

Dr Lam Tat Chung, Paul
林達聰醫生
FRCP, FHKAM (Medicine), FHKAM (Psychiatry)
President

Dr Lau Chu Pak
劉柱柏醫生
FRCP, MD, FHKAM (Medicine)
Chief Editor

CONTENTS

54 Major Depressive Disorder – Treatment Options Other Than SSRI
Dr Lam Tat Chung, Paul (林達聰醫生)

58 Long-term Treatment of Relapsing-Remitting Multiple Sclerosis
Dr Chan Koon Ho (陳灌豪醫生)

62 The Patient With Daily Headache
Dr Hui Che Fai, Andrew (許志輝醫生)

Major Depressive Disorder – Treatment Options Other Than SSRI

Dr Lam Tat Chung, Paul
(林達聰醫生)

FRCP, FHKAM(Medicine), FHKAM(Psychiatry)

Specialist in Psychiatry (Private Practice)

Hon. Clinical Assistant Professor, University of Hong Kong

Key words:
SSRI (選擇性血清素再吸收抑制劑), major depressive disorder (重度抑鬱症), NDRI (去甲腎上腺素-多巴胺再吸收抑制劑)

Depression is a complex syndrome that includes many different symptoms. With depressive mood as a core symptom, the condition is also associated with tiredness, loss of drive and motivation, poor concentration and cognitive functioning, impairment of attention or alertness, anhedonia and sexual dysfunction, agitation and irritability, aggression, anxiety, hypersomnia or insomnia, feeling of guilt, suicidality, dyscontrol of appetite and weight, and many associated physical symptoms.

The pharmacological treatment of depression evolves around the understanding and manipulation of the monoamine systems, namely the serotonergic, noradrenergic and dopaminergic systems. The interplay between these systems is not fully understood, but the adequacy and proper functioning of each of the monoamines has been shown to be important for the maintenance of a normal mood. Drugs have been developed to target each of the three systems to alleviate the disorder.

Currently, the most widely prescribed group of drugs for the treatment of depression is the selective serotonin reuptake inhibitors (SSRIs). This group of drugs is deemed as a great advance over the older antidepressants such as monoamine oxidase inhibitors (MAOIs) and tricyclics in terms of side effect profile and safety. Though a welcomed addition to the armamentarium, there remains many problems and inadequacies that need to be addressed or improved. These include the lack of efficacy in some patients, sexual dysfunction, weight gain, sedation, withdrawal symptoms, etc.

In the Sequenced Treatment Alternative to Relieve Depression (STAR*D) trial, an important large-scale study commissioned by the US National Institute of Mental Health, treatment with the SSRI citalopram for about 10 weeks resulted in a remission rate of only around 30%.[1]

An amotivational syndrome has been described in patients following use of SSRIs for several months. In these patients, although the depression improved, a state of apathy and indifference developed, which could be temporarily alleviated by a dose reduction of the SSRI. The addition of a noradrenergic agent improved the condition.[2,3] Other problems included bleeding tendencies and the syndrome of inappropriate antidiuretic hormone secretion.

Alternative medications have been developed to address the shortcomings of the SSRIs, and for the group of patients who require treatment for certain specific symptoms in the depressive syndrome by tackling different monoaminergic systems. (Table) While some medications modulate the noradrenergic system, bupropion is the only medication currently available that can effectively target the dopaminergic system as well. Different symptom groups that are controlled by

Table. Neurotransmitter effects of antidepressants

	Norepinephrine/noradrenaline (NE)	Serotonin (5-HT)	Dopamine (DA)
SSRIs		√	
Bupropion SR	√		√
Mirtazapine	√	√	
Nefazodone	√	√	
Venlafaxine	√	√	

SR = sustained release; SSRI = selective serotonin reuptake inhibitor

Figure 1. Different symptom groups controlled by serotonin, noradrenaline and dopamine



Adapted from reference 4.

the three different monoamines are illustrated in Figure 1.[4]

Bupropion is a monocyclic aminoketone that has been used for the treatment of major depression since 1989. It belongs to the class of norepinephrine-dopamine reuptake inhibitors (NDRIs). Sustained-release (SR) tablets (150 mg) were available in the US since 1996, and extended-release (XR) tablets (300 mg) since 2003.

Efficacy Studies

A pooled analysis of six randomized controlled trials showed that remission rate with bupropion was similar to SSRIs and better than placebo.[5] (Figure 2) Other studies have shown comparable remission rates with escitalopram and venlafaxine.[6-9] (Figure 3) Bupropion has also been shown to confer superior benefit in patients complaining of reduced energy, pleasure and interest.[10]

Treatment Switching

In the STAR*D trial, switching to bupropion SR, sertraline or venlafaxine resulted in similar remission rates of 26% to 28% in patients previously non-responsive to citalopram.[11]

Combination Therapy

In the above trial, the addition of bupropion SR resulted in a remission rate of 39% in patients previously not responding to citalopram alone. This is much better than the remission rate of 32.9% with buspirone augmentation. Other more favourable outcomes with the bupropion combination include treatment adherence, adverse reaction and change in the Quick Inventory of Depressive Symptomatology – Self Report (QIDS-SR) score.[12]

"Remission rate with bupropion was similar to SSRIs"

Other Benefits

Sexual dysfunction occurs in 20% to 60 % of patients treated with SSRIs. This may pose significant distress to depressed patients and compromise their quality of life. Bupropion is not associated with sexual dysfunction including orgasmic dysfunction, sexual arousal disorder and sexual desire disorder.[13]

Most antidepressants including SSRIs, mirtazapine, tricyclics and MAOIs cause weight gain. No such adverse effect is observed with bupropion. The agent may induce more weight loss than placebo in obese adults.[14]

Anxiety frequently occurs in depressed patients. Bupropion SR compares favourably with SSRI in the control of anxiety symptoms.[15]

Figure 2. Remission rates with bupropion and SSRIs: Pooled analysis of 6 RCTs



* Escitalopram (2), paroxetine (1), sertraline (3)
** p<0.0001 vs placebo
HAM-D = Hamilton Depression Rating Scale; RCT = randomized controlled trial; SSRI = selective serotonin reuptake inhibitor

Adapted from reference 5.

Figure 3. Remission rates with bupropion XR vs escitalopram



HAMD-17 = 17-item Hamilton Depression Rating Scale; XR = extended release

Adapted from reference 6.

Adverse Effects

The more frequent adverse effects are headache, insomnia, nausea, vomiting, dry mouth, and sweating.

Special Patient Groups

Bupropion has to be used with care in patients with hepatic failure or renal impairment. Caution should be exercised in patients prone to or with a history of seizure. The agent is classified under FDA Pregnancy Category B, while SSRIs are classified less favourably under Category C.

Conclusion

Bupropion SR (150 mg) given as a single morning dose is an appropriate and efficacious choice for the treatment of patients with major depressive disorder, or for combination therapy with SSRIs. Its unique mechanism of noradrenergic and dopaminergic reuptake inhibition makes it an effective antidepressant, with special benefit for symptoms such as loss of energy and motivation, tiredness, hypersomnia and anhedonia. It has special favourable profiles with regard to sexual function, body weight, control of anxiety symptoms and lack of sedation. In some patients, the dose can be increased to 150 mg twice daily if required.

References:

1. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
2. Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990;10:343-345.
3. Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE. A fluoxetine induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry 1991;52:131-133.
4. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997;11(4 suppl):S25-S31.
5. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60:1350-1355.
6. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-746.
7. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmcol 2006;26:482-488.
8. Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2009;23:531-538
9. GlaxoSmithKline. Data on file.
10. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:865-873.
11. Rush AJ, Trivedi MH, Wisniewski SR, et al; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Eng J Med 2006;354:1231-1242.
12. Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Eng Med 2006;354:1243-1252.
13. Thase, et al. Presented at: 159th (NR-602) American Psychiatric Association Annual Meeting; May 20-25, 2006; Toronto, Canada.
14. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-641.
15. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001;62:776-781.

A unique dual-acting treatment option for major depressive episodes

- **Bupropion is the only antidepressant to target noradrenaline and dopamine[1,2]**
  - Comparable antidepressant efficacy with SSRIs[1,3]
  - Significantly improves fatigue, interest and sleepiness[4,5]
  - Low incidence of serotonergic side effects such as sexual dysfunction and somnolence[1,3]
  - No weight gain during long term use[6]
- **Over 40 million patients treated with Bupropion[1*]**
- **Wellbutrin SR dosage**



References:
1. Fava M., Rush A.J., Thase M.E., Clayton A., Stahl S.M., Pradko J.F., Johnston J.A. Prim Care Companion J Clin Psychiatry 2005;7:106-113
2. Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., Learned-Coughlin. Prim Care Companion J Clin Psychiatry 2004;6:159-166
3. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., VanMeter S., Harriett A.E., Wang Y.W. J Clin Psychiatry 2005;66:974-981
4. Baldwin D.S. and Papakostas G.I. J Clin Psychiatry 2006;67(supp 6).
5. Jamerson B.D., Krishnan K.R.R, Robert J., Krishen A. Modell J.G. Psychopharmacology Bulletin 2003. Vol. 37 No 2-67
6. Croft H., Houser T.L., Jamerson B.D, Leadbetter R., Bolden-waston C., Donahue R, Metz A. Clinical Therapeutics 2002;24:662-672

*Bupropion is approved for use in over 50 countries for the treatment of major depressive disorder and / or as an aid to smoking cessation under the brand name of Zyban™ (data on file, GlaxoSmithKline Research Triangle Park, N.C.)

WELLBUTRIN SR ™ abridged prescribing information

INDICATIONS WELLBUTRIN SR is indicated for the treatment of depression. **DOSAGE AND ADMINISTRATION** WELLBUTRIN SR should be swallowed whole and not crushed, divided, or chewed. Initial Treatment: Usual adult target dose: 300 mg/day (150 mg twice daily). Starting dose: 150 mg/day given as a single daily dose in the morning. If the 150 mg initial dose is adequately tolerated, an increase to the 300 mg/day target dose may be made as early as day 4 of dosing. There should be an interval of at least 8 hrs between successive doses. Maximum dose: 400 mg/day. Maintenance Treatment: Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment. Patients with Impaired Hepatic Function: Use with caution in patients with hepatic impairment (including mild to moderate hepatic cirrhosis) and with extreme caution in patients with severe hepatic cirrhosis. Patients with Impaired Renal Function: Use with caution in patients with renal impairment. **CONTRAINDICATIONS** Patients with hypersensitivity to bupropion or any of the other components of the preparation. Patients with a seizure disorder. Patients undergoing abrupt discontinuation of alcohol or sedatives. Patients currently being treated with any other preparation containing bupropion as the incidence of seizures is dose dependent. Patients with a current or previous diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was seen in this patient population when bupropion was administered. Concomitant use of bupropion and monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between discontinuation of irreversible MAOIs and initiation of treatment with bupropion. **WARNINGS AND PRECAUTIONS** The recommended dose of sustained release bupropion tablets should not be exceeded, since bupropion is associated with a dose-related risk of seizure. Extreme caution to patients with one or more conditions predisposing to a lowered seizure threshold. Caution should be used in those clinical circumstances associated with an increased risk of seizures. Bupropion should be discontinued and not recommenced in patients who experience a seizure while on treatment. Bupropion should be discontinued promptly if patients experience hypersensitivity reactions during treatment. Bupropion should be used with caution in patients with hepatic impairment and reduced frequency of dosing should be considered in patients with mild to moderate hepatic cirrhosis. Bupropion should be used with extreme caution in patients with severe hepatic cirrhosis. Treatment of patients with renal impairment should be initiated at reduced dosage. Patients with hepatic or renal impairment should be closely monitored for possible adverse effects (e.g., insomnia, dry mouth, seizures) that could indicate high drug or metabolite levels. Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents <18 years with major depressive disorder and other psychiatric disorders. Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications. This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases. It is general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stages of recovery. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Neuropsychiatric symptoms have been reported. In particular, psychotic and manic symptomatology has been observed, mainly in patients with a known history of psychiatric illness. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. There is limited clinical experience of the use of bupropion to treat depression in patients with cardiovascular disease. Care should be exercised if it is used in these patients. **INTERACTIONS** Care should be exercised when bupropion is co-administered with drugs known to affect the CYP2B6 isoenzyme. Concomitant therapy with drugs predominantly metabolised by this isoenzyme should be initiated at the lower end of the dose range of the concomitant medication. If bupropion is added to the treatment regimen of a patient already receiving a medication metabolised by CYP2D6, the need to decrease the dose of the original medication should be considered. Rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients drinking alcohol during bupropion treatment. Administration of bupropion to patients receiving either levodopa or amantadine concurrently should be undertaken with caution. Studies suggest that exposure to bupropion may be increased when sustained release bupropion tablets are taken with food. Concomitant use of bupropion and a Nicotine Transdermal System (NTS) may result in elevations of blood pressure. Interactions have been reported with citalopram and ritonavir. Exercise caution before driving or use of machinery until they are reasonably certain bupropion does not adversely affect their performance. **PREGNANCY AND LACTATION** Administration of bupropion should only be considered during pregnancy if the expected benefits are greater than the potential risks. As bupropion and its metabolites are excreted in human breast milk, mothers should be advised not to breast feed while taking immediate release, sustained release or extended release bupropion tablets. **ADVERSE REACTIONS** Hypersensitivity reactions such as urticaria. Anorexia. Weight loss. Insomnia. Agitation, anxiety. Depression, confusion. Headache. Tremor, dizziness, taste disorders. Concentration disturbance. Seizures. Visual disturbance. Tinnitus. Tachycardia. Increased blood pressure (sometimes severe), flushing. Dry mouth, gastrointestinal disturbance including nausea and vomiting. Abdominal pain, constipation. Rash, pruritus, sweating. Fever, chest pain, asthenia. **OVERDOSAGE** In addition to those events reported under Adverse Reactions, overdose has resulted in symptoms including drowsiness, loss of consciousness and ECG changes such as conduction disturbances (including QRS prolongation) or arrhythmias. In the event of overdose, hospitalisation is advised. ECG and vital signs should be monitored. Ensure an adequate airway, oxygenation and ventilation. Gastric lavage may be indicated if performed soon after ingestion. The use of activated charcoal is also recommended. No specific antidote for bupropion is known.

™ WELLBUTRIN is a trademark of the GlaxoSmithKline group of companies.
Full prescribing information is available on request. Please read the full prescribing information prior to administration.

GlaxoSmithKline
23/F Tower 6 The Gateway
9 Canton Road
Tsimshatsui
Kowloon Hong Kong
Tel: 31898989 Fax: 31898931

Wellbutrin SR™
(bupropion hydrochloride)
Sustained-Release Tablets 150mg

The only Noradrenaline & Dopamine Re-uptake Inhibitor.

N09WB221/02072009

Long-term Treatment of Relapsing-Remitting Multiple Sclerosis

Dr Chan Koon Ho (陳灌豪醫生)

MD (HK), MRCP (UK), MBBS (HK), FHKCP, FHKAM (Medicine), FRCP (Glasgow)

University Department of Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, University of Hong Kong

Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, University of Hong Kong

Key words:
Relapsing-remitting multiple sclerosis (復發緩解型多發性硬化), beta-interferons (乙型干擾素), natalizumab

Introduction

Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by inflammatory demyelination of the central nervous system (CNS).[1,2] Approximately 85% of patients with classical MS (CMS) have relapsing-remitting MS (RRMS) at onset, characterized by recurrent attacks of inflammatory demyelination and axonal injury affecting different sites of the CNS. About 90% of CMS patients have oligoclonal bands (OCB) in cerebrospinal fluid (CSF).[1,2] Asians have a lower prevalence of CMS than Caucasians; it has been reported that relatively higher proportions of Asian MS patients have opticospinal MS (OSMS), in which there is predominant involvement of optic nerves and spinal cord, and a lower frequency of CSF OCB.[3,4] Recent evidence strongly suggests that OSMS is in fact neuromyelitis optica (NMO), also called Devic's disease, which is distinct from CMS.[5,6] RRMS patients develop recurrent attacks of inflammatory demyelination affecting the cerebral hemispheres, brainstem, cerebellum, spinal cord (myelitis) and optic nerves (optic neuritis), which are associated with good neurological recovery especially in early attacks; in contrast, relapsing NMO patients typically develop recurrent severe attacks of myelitis and optic neuritis associated with early irreversible neurological disabilities.[6-8] Importantly, CMS patients are seronegative for NMO-immunoglobulin G (IgG), an autoantibody targeting the aquaporin-4 water channel and a specific biomarker for NMO, while about 60% to 73% of NMO patients are seropositive for NMO-IgG.[5] Hence, early serological testing for NMO-IgG is useful in prompt diagnosis of NMO and its distinction from CMS in patients who present with myelitis or optic neuritis.[5]

Most RRMS patients have satisfactory recovery from acute attacks in the early phase; unfortunately, an accumulating number of patients will develop secondary progressive MS (SPMS) characterized by irreversible progressive neurological deterioration and disability accumulation with or without acute relapses.[1,2,9,10] Natural history studies estimate that RRMS patients develop SPMS at a rate of 2% to 3% per year,[1,2,9-17] and the median time to reach the Expanded Disability Status Scale (EDSS) score of 6 (ie, need of unilateral assistance to walk for 100 metres) is estimated to be about 19 years.[14] Axonal degeneration is believed to be the key pathology underlying SPMS.[18] Importantly, axonal injury can occur and be severe early in RRMS.[18-21] Hence, in the absence of effective treatments that can prevent or delay progression to SPMS, the majority of RRMS patients are at risk of significant neurological disability in the long term in view of the chronic nature and predominantly young onset age of this disorder.

Aetiological Factors

The exact pathogenetic mechanisms of MS are uncertain.[1,2,22] Genetic factors contribute to its aetiology as evidenced by the concordance rate of 31% among monozygotic twins vs 5% for dizygotic twins; moreover, the presence of the HLA-DR2 antigen increases an individual's susceptibility to CMS.[2,23] Multiple genes influence the susceptibility to developing MS, but no single gene with the possible exception of HLA has a strong influence.[1,2]

Environmental factors also play a role, as evidenced by the change in MS frequency among individuals and their offspring who migrate into and out of high-prevalence areas.[24] Infection by micro-organisms including herpes simplex virus type 6 and *Chlamydia pneumoniae* is suggested to be a causative factor,[25,26] but confirmation from other studies is lacking.

Diagnosis

The diagnosis of RRMS is suggested by a history of recurrent attacks of injury to different sites of the CNS, followed

by partial or complete resolution of symptoms. Physical findings of abnormalities at multiple CNS sites such as cerebellar ataxia from cerebellar involvement and paraparesis with a sensory level from spinal cord involvement support the diagnosis. Magnetic resonance imaging (MRI) of multiple white matter lesions at different sites of the CNS (ie, spatial dissemination) and lesions with different ages (ie, temporal dissemination, shown by new lesions on repeated MRI) greatly facilitate the diagnosis, especially in patients who presented with the first clinical attack, known as clinically isolated syndrome (CIS), based on fulfillment of the revised McDonald criteria.[27] Lumbar puncture for exclusion of CNS infection and detection of CSF OCB helps to support the diagnosis. Other disorders that mimic RRMS must be excluded, especially relapsing NMO (by testing for NMO-IgG) and vasculitis such as cerebral lupus (by testing for autoimmune markers including antinuclear antibody [ANA] and anti-extractable nuclear antigen [anti-ENA] antibody).

Treatments

Aims and Approach

Treatment aims at: 1) reduction of relapse rate, 2) prevention of fixed disability directly attributable to relapse, 3) symptomatic treatment of fixed neurological deficits, and 4) prevention or delay of development of SPMS, hence minimizing permanent disability. It is encouraged to adopt a multidisciplinary team approach, in which different professionals including neurologist, nurse specialist, physiotherapist, occupational therapist, rehabilitation specialist and clinical psychologist contribute to patient care by providing expertise in management of a chronic neurological disorder. This review will address the long-term pharmacological treatment of RRMS.

Long-term Disease-modifying Drugs

Intravenous pulse methylprednisolone 0.25–1 g daily for 3 to 5 days is indicated during acute attacks associated with potentially significant disability to hasten neurological recovery; however, the benefit on long-term neurological disability is uncertain.[1,2] Regular intermittent intravenous pulse corticosteroid and regular oral corticosteroid therapies are ineffective for reduction of relapse frequency. Currently, four disease-modifying drugs (DMDs) are approved for use in RRMS. These are beta-interferon (β-IFN) (1a and 1b), glatiramer acetate (GA), natalizumab and mitoxantrone.[2]

Beta-interferon

β-IFN 1a and 1b are first-line immunomodulatory therapies for RRMS. Their short-term efficacy (for 2 to 3 years) in reducing relapse frequency by about one-third is well proven.[28-30]

β-IFN 1a and 1b possess anti-inflammatory properties, inhibit T cell activation and reduce blood-brain barrier permeability to inflammatory cells.[28] Therapy requires subcutaneous injection 3 times a week or on alternate days. Common side effects are local injection site reactions, flu-like symptoms with fever (which tend to subside after several weeks in most patients who continue with therapy), and reversible liver function derangement as evidenced by raised parenchymal liver enzyme levels.[28] In addition, 5% to 30% of treated patients develop persistent neutralizing antibodies that are associated with reduced treatment effect on relapse frequency.[2] Long-term benefits in prevention or reduction of disability are uncertain, and patients or carers need to perform subcutaneous injection. The ideal timing for starting β-IFN in RRMS is controversial.[31,32] The author is in favour of early initiation of DMD once the diagnosis of RRMS is confirmed and when the disease is active, as evidenced by clinical relapse or MRI evidence of subclinical active inflammation.

Glatiramer Acetate

GA is a synthetic co-polymer structurally similar to myelin basic protein (MBP). Therapy requires daily subcutaneous injection. GA is thought to induce T cell anergy, inhibition of MBP-reactive T lymphocytes and induction of T helper 2 lymphocytes, resulting in an anti-inflammatory action.[33] GA reduces relapse frequency of RRMS by about 30%, and improves MRI parameters of disease activity. Its efficacy is similar to that of β-IFN. GA is generally safe and well tolerated. Similar to β-IFN, its benefit on long-term disability is uncertain.

Natalizumab

Lymphocyte migration across the blood-brain barrier is an important early step in the formation of lesions in MS.[1,22] α_4 integrins are a family of adhesion molecules expressed on the surface of lymphocytes, functioning as an important mediator of cell adhesion and transendothelial migration, and a regulator of immune cells activation within inflamed tissue.[34,35] Natalizumab is a humanized monoclonal antibody against the α_4 integrins, which selectively blocks the binding of $\alpha_4\beta_1$ and $\alpha_4\beta_7$ integrins to their endothelial receptors, hence inhibiting migration of lymphocytes into the brain and reducing inflammation.

A randomized double-blind trial of 213 patients with RRMS or relapsing SPMS treated with intravenous natalizumab (3 mg/kg or 6 mg/kg) or placebo every 28 days for 6 months showed that active treatment was associated with reductions in relapse frequency and the number of new enhancing brain lesions over the 6-month period. However, such differences disappeared upon an additional 6 months' follow-up.[36]

More recently, natalizumab was shown to be effective in RRMS by reducing the relapse rate at 1 year by 68%, and the risk of sustained progression of disability by 42% over 2 years in a 2-year phase III clinical trial.[37] The cumulative probability of progression was 17% in the natalizumab group vs 29% in the placebo group. Furthermore, the addition of natalizumab to β-IFN 1a reduced the risk of disability progression by 24% and annualized relapse rate by 55% over a 2-year period, compared with β-IFN 1a alone.[38]

Currently, natalizumab is recommended for RRMS patients who failed to respond to β-IFN, or RRMS patients with very aggressive disease that may be stabilized with natalizumab first followed by stepping down of therapy to β-IFN or GA. Some patients will develop neutralizing antibodies against natalizumab, which may cause hypersensitivity reactions and loss of drug efficacy over time. Patients reacting to or showing poor response to natalizumab may need testing for anti-

bodies. Importantly, patients treated with natalizumab, especially when preceded by other immunosuppressant therapy or used in combination with β-IFN, rarely develop progressive multifocal leukoencephalopathy (PML) due to latent JC virus infection. The risk of PML related to natalizumab therapy is estimated to be 1 in 1,000 (0.1%) over an 18-month treatment period.[39] It is generally accepted that the beneficial effects of natalizumab in active RRMS outweigh the risk of PML.[40]

Mitoxantrone

Mitoxantrone is a synthetic anthracenedione with cytotoxic and immunosuppressive effects. It inhibits DNA repair and synthesis in dividing and non-dividing cells by inhibiting DNA topoisomerase II, suppresses T and B cells, induces apoptosis in antigen-presenting cells, and deactivates macrophages.[41,42] A randomized double-blind trial of 194 patients with worsening RRMS or SPMS treated with mitoxantrone (5 mg/m^2 or 12 mg/m^2) or placebo 3-monthly for 2 years showed that mitoxantrone offered significant benefits over placebo for the primary outcome, which was a composite of five clinical measures: ambulation index, standard neurological status, change from baseline in EDSS, number of relapses treated with corticosteroids, and time to first treated relapse.[43]

Mitoxantrone provides short-term benefits by reducing relapse rate, development of new cerebral lesions on MRI, and number of patients who experience deterioration of neurological function.[43-45] However, these studies were in a relatively small number of patients, and benefits on disability were not established.

Serious potential side effects of mitoxantrone include dose-related impairment of left ventricular ejection fraction and irreversible congestive heart failure when the cumulative lifetime dose exceeds 140 mg/m^2 (use of mitoxantrone is limited to a maximum of 3 years at current dosage), birth defects when given during pregnancy or time of conception to both male and female partners, sterility that may be permanent, and rarely leukaemia.

Mitoxantrone is recommended for use as induction therapy in very active RRMS or as rescue treatment if patients do not respond to β-IFN or GA. It is licensed in the US for use in aggressive RRMS patients and SPMS patients with high relapse frequency, and recommended for patients with unsatisfactory response to high-dose β-IFN or those with rapidly progressive disease.[46] Most recently, serious side effects of mitoxantrone, including congestive heart failure and therapy-related acute leukaemia, are reported to be more frequent than previously believed.[47] With the availability of natalizumab, mitoxantrone use is becoming uncommon and less preferred.

Conclusion

DMDs should be considered for RRMS patients with active disease, but the timing of therapy initiation and the choice of DMDs should be individualized in view of differences in disease severity, relapse frequency, lifestyles, personal preference and funding support for these expensive therapies.

References:

1. Noseworthy JH, Lucchinetti CF, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Eng J Med 2000;343:938-952.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.
3. Yu YL, Woo E, Hawkins BR, Ho HC, Huang CY. Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989;112(pt 6):1445-1467.
4. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
6. Weinshenker BG. Neuromyelitis optica: What it is and what it might be. Lancet 2003;361:889-890.
7. Chan KH, Tsang KL, Fong GC, Cheung RT, Ho SL. Idiopathic severe recurrent transverse myelitis: A restricted variant of neuromyelitis optica. Clin Neurol Neurosurg 2005;107:132-135.
8. Chan KH, Tsang KL, Fong GCY, Cheung RTF, Ho SL. Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. Eur J Neurol 2006;13:862-868.
9. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989;112(pt 1):133-146
10. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114(pt 2):1045-1056.
11. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med 1952:21:135-167.
12. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. J Chronic Dis 1977;30:819-830.
13. Poser S, Bauer HJ, Poser W. Prognosis of multiple sclerosis. Results from an epidemiological area in Germany. Acta Neurol Scand 1982;65:347-354.
14. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
15. Detel R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP. Factors associated with a rapid course of multiple sclerosis. Arch Neurol 1982;39:337-341.
16. Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand 1984;70:321-328.
17. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol 2004;56:303-306.
18. Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003;74:695-697.
19. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in multiple sclerosis lesions. Brain 1997;120(pt 3):393-399.
20. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999;122(pt 10):1933-1939.
21. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesion of multiple sclerosis. N Eng J Med 1998;338:278-285.
22. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996;85:299-302.
23. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-1225.
24. Dean G. Annual incidence, prevalence, and mortality of multiple sclerosis in white South- African-born and in white immigrants to South Africa. BMJ 1967;2:724-730.
25. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995;92:7440-7444.
26. Siriam S, Stratton CW, Yao SY, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999;46:6-14.
27. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-846.
28. Goodin DS, Frohman EM, Garmany GP, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
29. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
30. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
31. Frohman EM, Havrdova E, Lublin F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006;63:614-619.
32. Pittock SJ, Weinshenker BG, Noseworthy JH, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006; 63:611-614.
33. Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000;55:1704-1714.
34. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α4 integrin by CD4 T cells is required for entry into brain parenchyma. J Exp Med 1993;177:57-68.
35. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 intergrins in vivo. J Clin Invest 1994;94:1722-1728.
36. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2003;348:15-23.
37. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2006;354:899-910.
38. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med 2006;354;911-923.
39. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med 2006;354:924-933.
40. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analyses of natalizumab. Neurology 2008;71:357-364.
41. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727-732.
42. Fidler JM, DeJoy SQ, Smith FR, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986;136:2747-2754.
43. Hartung HP, Gonsette R, Konig N, et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002;360:2018-2025.
44. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
45. Millerfiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
46. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-1338.
47. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-1466.

* Maximum recommended dose is 800mg/day. Effective dose range: 400mg to 800mg/day, depending on clinical response and tolerability of the patient.

Abbreviated Prescribing Information:
Presentation: Quetiapine fumarate extended-release tablet. **Indications:** Treatment of Schizophrenia & preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. **Dosage: Adults: Schizophrenia:** Once-daily, without food (at least one hr before meal. Starting daily dose is: 300mg (Day 1) & 600mg (Day 2). Recommended daily dose is 600mg. Range 400-800mg/day depending on clinical response & tolerability of patient. **Switching from Seroquel IR:** Switch at equivalent total daily dose. Individual adjustments may be necessary. *Elderly or hepatic impairment patients:* Initially 50mg/day increased in increments of 50mg/day to an effective dose. *Renal impaired patients:* No dosage adjustment needed. **Contraindications:** Hypersensitive to any component of this product. **Precautions:** Neutropenia; increases in blood glucose and hyperglycaemia; cardiovascular disease & cerebrovascular disease; Conditions predisposing to hypotension; seizures; tardive dyskinesia; neuroleptic malignant syndrome; acute withdrawal symptoms; elderly patients with dementia; patients who need to drive or operate machinery; pregnancy & lactation. **Interactions:** Centrally acting drugs; alcohol; thioridazine; carbamazepine, phenytoin, barbiturates, rifampicin; azole antifungals; macrolide antibiotics and protease inhibitors. **Undesirable effects:** Dry mouth; dizziness; somnolence; leukopenia; tachycardia; constipation; dyspepsia; mild asthenia; peripheral edema; weight gain; elevations in serum transaminases (ALT, AST), neutrophil count decreased; blood glucose increased to hyperglycaemic level; syncope; rhinitis and orthostatic hypotension.
Full local prescribing information is available upon request. API.HK.SER.0208

Seroquel XR is a trade mark of the AstraZeneca group of companies.

Reference: 1. Seroquel XR Package Insert Version: Feb 2008.

www.SEROQUEL.info

AstraZeneca

Further information is available on request
AstraZeneca Hong Kong Limited
18/F, Shui On Centre, 6-8 Harbour Road
Wanchai, Hong Kong
Tel : 2420 7388 Fax : 2422 6788

Once Daily
Seroquel XR™
quetiapine

HK-1511.09(09.2)23 09/2009

The Patient With Daily Headache

Dr Hui Che Fai, Andrew (許志輝醫生)

MBBS (Lond), DTM&H, FHKAM, FHKCP, FRCP (Edin), FRCP (Lond)

Specialist in Neurology, PacifiCare

Key words:
Migraine (偏頭痛), headache (頭痛)

Introduction

Physicians often come across patients who complain of frequent headaches. Most have episodic pain, but sometimes the headaches are present on a daily basis. Chronic daily headache (CDH) is a common problem, affecting around 5% of the general population; children as well as adults may be affected. It is not a single entity but a heterogeneous group of disorders, occurring by definition 15 days per month for over 3 months.[1,2]

Primary headaches refer to disorders that have no clear structural cause and are described as "benign", but the associated disability can be substantial – depression, anxiety, impaired occupational and physical status. Primary CDH is categorized according to the duration of each episode – whether they last longer or shorter than 4 hours. (Table 1) Some headaches last for only a few seconds or minutes, the most well known of which is trigeminal neuralgia. Others include cluster headache, hypnic headache, paroxysmal hemicrania, primary stabbing headache, and short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome (SUNCT). The focus of this article is the first category in which episodes last for more than 4 hours. In this group, there are four forms of headache disorders: chronic migraine (previously called transformed migraine), chronic tension-type headache, new daily-persistent headache and hemicrania continua.

Table 1. Differential diagnosis of primary chronic daily headache

Headache duration >4 hours

- Chronic migraine
- Chronic tension-type headache
- New daily persistent headache
- Hemicrania continua

Headache duration <4 hours

With autonomic features

- Cluster headache
- Paroxysmal hemicrania
- Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome (SUNCT)

Without autonomic features

- Trigeminal neuralgia
- Idiopathic stabbing headache

Headaches are secondary if attributed to an underlying cause such as tumours, infection or inflammation.

Diagnosis

The first step in evaluation is to look for potentially serious pathology. This would be suspected in particular if certain red-flag features are present. (Table 2)

Table 2. Features suggesting a secondary cause of headache

- Systemic illness
- New physical sign
- Sudden onset
- Onset age >40 years
- Progressive worsening of headache
- Worst ever headache
- Headache worsening with cough

Many individuals with chronic headache are concerned about a brain tumour or stroke. In practice, patients with a stable pattern of headache for 1 year usually do not have significant intracranial lesions. If the cranial magnetic resonance imaging (MRI) is normal, patients may feel relieved but frustrated because from their point of view, the pain remains "unexplained". In few other neurological complaints are detailed history and examination as vital because there are no discriminatory laboratory or radiological tests. Once secondary headaches have been excluded, the criteria for primary CDH are clinical and descriptive. The International Headache Society has published a useful but exhaustive classification of headache disorders, which is over 200 pages long plus references, on its website.[3]

Chronic Migraine

Often, chronic migraine is preceded by a history of episodic migraine, which has increased in frequency over months and years until the patient suffers from daily migraneous or nonmigraneous headaches. The characteristic symptoms such as auras, photophobia, phonophobia and nausea may decrease during this transformation period. Risk factors for migraine transformation include female gender, obesity, frequent headaches at baseline and stressful life events.

Chronic Tension-type Headache

Most patients have bilateral nonthrobbing headache without migraine features such as aura, photophobia or nausea. This usually evolves from episodic tension headache and has a pressing or "tightening" quality. The attacks are not aggravated by walking or head movements.

New Daily Persistent Headache

New daily persistent headache (NDPH) is a recently recognized form of primary CDH first described in 1984. It occurs in a person with no past history of headache although this is not an absolute factor. Typically, most patients can recall the exact day on which the pain started, and have experienced daily headache since that time. The diagnostic criteria for NDPH stipulate that pain must be present daily

Table 3. Hemicrania continua

A. Headache for more than 3 months fulfilling three other criteria from B to D below.

B. All of the following characteristics:

- Unilateral pain without side-shift
- Daily and continuous, without pain-free periods
- Moderate intensity, but with exacerbations of severe pain

C. At least one of the following autonomic features that occurs during exacerbations and is ipsilateral to the side of pain:

- Conjunctival injection and/or lacrimation
- Nasal congestion and/or rhinorrhoea
- Ptosis and/or miosis

D. Complete response to therapeutic doses of indomethacin

E. Not attributed to another disorder

for more than 2 months with a duration of longer than 4 hours a day. The headaches are usually bilateral in location, and are described as throbbing or pressing in quality, with associated symptoms such as nausea, light sensitivity, sound sensitivity, or light-headedness in more than half of the sufferers.

Hemicrania Continua

This is an uncommon condition and is a strictly unilateral headache disorder. The definition as adopted by the most recent 2nd edition of the International Classification of Headache Disorders is in Table 3.[2] It is important to recogize this form of CDH as it can be confused with cluster headache, and treatment for it can be quite effective.

Medication Overuse Headache

All the headache disorders described above can be intensified by the overuse of prescription or over-the-counter analgesics. In fact, the majority of patients who are referred to headache clinics exhibit analgesic overuse. The problem begins with individuals taking one or more drugs to treat headaches over an extended period; this paradoxically leads to more frequent pain and shortening periods between headache recurrence and drug consumption. Patients who consume simple analgesics such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for ≥15 days per month are at risk of medication overuse headache. The threshold is reduced to ≥10 days for drugs such as ergotamine, triptans and combination drugs.

Treatment

Treatment of CDH is challenging as usually there is no instant solution and sufferers may have consulted many other doctors and healthcare professionals. The objectives of treatment are to reduce the frequency, severity and duration of attacks, to reduce disability, and to improve daily function. A headache diary is advisable to document the frequency of attacks and analgesic consumption. First-line therapy is with advice on behavioural adjustments such as regular exercise, good sleep hygiene, trigger avoidance, stress reduction and a migraine diet. Some patients may obtain relief from psychotherapy or cognitive behaviour therapy, and there is anecdotal success with yoga and meditation. Medication overuse, if present, should be managed by stopping the offending drugs and using transition therapy with other analgesics such as NSAIDs or a short course of steroids.[4] Sometimes inpatient detoxification regimens can be tried, in which the abused drug should be stopped and preventive drugs started along with anxiolytics, antiemetics and rescue therapy.

The mainstay of treatment of CDH is prophylactic drug therapy; most studies have concentrated on tricyclic antidepressants (amitriptyline, nortriptyline), anticonvulsants (valproate, topiramate, gabapentin, pregabalin) and beta-blockers (propranolol, atenolol, metoprolol).[5] Selective serotonin reuptake inhibitors (fluoxetine) are useful in those with associated psychiatric comorbidity. Botulinum toxin is expensive but can lead to marked improvement.

Patients who do not respond to first-line treatment may need multiple prophylactic drugs to control headache attacks. Those with refractory headaches may be referred for specialist assessment for review of the diagnosis (to look for unusual causes such as idiopathic intracranial hypertension and define the type of headache), and for management of chronic pain and medication overuse. Multidisciplinary care is required for patients with psychiatric morbidity and chemical dependency.

References:

1. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995;15:45-68.
3. International Headache Society. HIS Classification ICHD-II. Available at: http://ihs-classification.org/en/02_klassifikation/02_teil1/04.07.00_other.html. Accessed July 4, 2010.
4. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre – clinical characteristics and treatment outcomes. Cephalalgia 2004;24:483-490.
5. Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006;354:158-165.

The Editorial Board appreciates your comments and suggestions.

Please send you messages to Dr. Lam Tat Chung, Paul (林達聰醫生)

at drtclam@gmail.com or by fax to 2868 1530

Triad of Neuropathic Pain

3 Different Problems
1 Simple Solution

- **Advanced Treatment for Neuropathic Pain**
  Powerful pain relief as early as after the 1st full day of treatment[1]
- **A New Class for Generalized Anxiety Disorder (GAD)[2]**
  Rapid relief of both psychic and somatic symptoms at week 1[3]
- **Novel Sleep Architecture Benefits**
  Significantly reduced sleep onset latency and increased slow-wave sleep proportion compared with placebo[4]

*Symptoms of neuropathic pain

References: **1.** Dworkin RH, et al. Neurology 2003;60:1274-1283. **2.** Rickels K., et al. Arch Gen Psychiatry 2005; 62:1022-1030. **3.** Montgomery SA, et al. J Clin Psychiatry 2006; 67:771-782. **4.** Ian Hindmarch, et al. Sleep 2005; Vol 28, No.2. **Full prescribing information is available upon request.**

Pfizer Corporation Hong Kong Limited
16/F., Stanhope House, 738 King's Road, North Point, Hong Kong
Tel: (852) 2811 9711 Fax: (852) 2579 0289
Website: www.pfizer.com.hk

TOTAL PAIN MANAGEMENT

LYRICA® PREGABALIN

LYRICA/2P

Aricept®
Giving Alzheimer's patients time

Treating Alzheimer's is a race against time

- **Aricept®** is a truly once-a-day regimen[1]
- **Aricept®** needs no sub-therapeutic titration step[1]
- **Aricept®** is the only AChEI approved for mild, moderate and severe Alzheimer's disease[1]
- **Aricept®** is the most widely prescribed AChEI in the world[2]

References: 1. Aricept Product Information and Data on file. **2.** IMS data, MIDAS, 2Q MAT 2009.

Further information is available upon request.
hhc Eisai Human Health Care Company

EISAI (HONG KONG) CO. LTD.
Rm. 2008 Fortress Tower, 250 King's Road.,
North Point, Hong Kong
Tel: (852) 2516 6128 Fax: (852) 2561 5042

HK-AT-IV-10G-03

AMONG TOPICAL MEDICATIONS ...

nothing works better for ladies with dark spots

Tri-Luma® Cream provides the aesthetic relief that patients with melasma are looking for[1]

Tri-Luma® CREAM
Let women be themselves again.

The only FDA-approved triple combination topical for melasma

www.triluma.com

Tri-Luma® Cream should be used with measures for sun avoidance, like using Cetaphil® UVA/UVB Defense. Exposure to sunlight, sunlamps, or UV light and extreme heat, wind, or cold should be avoided. Tri-Luma® Cream contains sulfites. People allergic to sulfites should not use Tri-Luma® Cream. In addition, redness, peeling, burning, dryness, and itching may occur. Please see packing insert for full prescribing information.

Galderma Hong Kong Ltd. Tel +852 2824 0333 Fax +852 2827 7760
Unit 1401, 14/F, Ming An Plaza, Phase 1, 8 Sunning Road, Causeway Bay, Hong Kong.

GALDERMA
Committed to the future of dermatology

TRI-AD001-0309

1. Torok H, Taylor S, Baumann L et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combinaton (TC) cream in melasma patients previousy treated with TC cream or one of it dyads. J Drugs Dermatol 2005;4: 592-7.